View the content of this email online

A new approach to gene editing without integration!

News Electroportation Test 1
Use LentiFlash, the next generation of non-integrative lentiviral vectors based on bacteriophage MS2 coat protein!
Separator

LentiFlash™-CRISPR-Cas9 particles allow efficient KO of genes of interest in human primary T cells for multiple applications such as:

  • Cancer immunotherapy approach (discover data on efficient editing of PD1)
  • Antiviral strategies (discover data on efficient editing of CXCR4)
  • All this by guaranteeing a safe and efficient gene transfer even in primary T cells

LentiFlash delivers non-viral RNA into target cells:

  • For gene editing experiments in vitro and in vivo with CRE-lox system
  • For lineage commitment and cell engineering
  • Absence of integration is guaranteed
Scalable and reproducible production process

To discover data gathered by Vectalys
Click Here
Eprouvette

Maecenas sed ante pellentesque, posuere leo id, eleifend dolor.

Maecenas sed ante pellentesque, posue dolor. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.
Read more
Cellule

Lentisflashs sed ante pelle en tesque eleifend dolor.

Maecenas sed ante pellentesque, posue dolor. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.
Read more

Follow us

Twitter Flash Therapeutics LinkedIn Flash Therapeutics Youtube Flash Therapeutics
www.flashtherapeutics.com
© Flash Therapeutics 2018

Click here to unsuscribe from the mailing list